MPM BioImpact

238 posts

MPM BioImpact banner
MPM BioImpact

MPM BioImpact

@MPMBioImpact

Investing in Healthcare Innovation

Boston, MA Katılım Haziran 2009
117 Takip Edilen1.5K Takipçiler
MPM BioImpact
MPM BioImpact@MPMBioImpact·
ICYMI: @orna_tx announced the appointment of Joe Bolen, Ph.D., as CEO! Joe most recently served as Orna’s Chief Scientific Officer and is the ideal leader to advance its potentially best-in-class panCAR programs into the clinic next year. ornatx.com/orna-therapeut…
English
0
0
0
152
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Congrats to @CullinanTx which announced that its Phase 2b trial in patients with NSCLC met its primary endpoint! Cullinan was founded and built by MPM BioImpact and is committed to treating a variety of cancer and autoimmune disorders with high unmet medical needs.
Cullinan Therapeutics@CullinanTx

Today, we announced the Phase 2b REZILIENT1 trial of zipalertinib in patients with non-small cell lung cancer (#NSCLC) met its primary endpoint of overall response rate. Zipalertinib is being developed in partnership with Taiho Pharmaceutical and @TaihoOncology. Learn more.

English
0
0
1
211
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Congrats to Dr. Pelka! We are proud to partner with AACR to support high-risk, high-reward research, which may catalyze scientific discoveries and change clinical practice. We look forward to your potential impact on the treatment of mismatch repair-proficient colorectal cancer.
AACR@AACR

We congratulate Karin Pelka, PhD, recipient of an AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant. Dr. Pelka aims to induce anti-tumor immunity hubs in mismatch repair-proficient colorectal cancer, at least in part by using CAR T cells. @MPMBioImpact

English
0
0
0
190
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Congrats to Dr. Danial! We are excited to partner with AACR to fund paradigm-shifting research, which may advance our understanding of cancer and transform future clinical practice, and we are delighted to support the efforts to impact the treatment of glioma.
AACR@AACR

We congratulate Nika Danial, PhD, recipient of an AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant. Dr. Danial aims to identify lipid-targeted molecular regulators of H3K27M glioma growth by using proteomics and CRISPR-based approaches. @MPMBioImpact

English
0
0
0
257
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Two portfolio companies built by MPM BioImpact have joined forces: @orna_tx acquires @ReNAgadeTx, uniting the leading circular RNA technology (oRNA®) for in vivo CARs with best-in-class lipid nanoparticle (LNP) delivery solutions for RNA. Learn more: mpmbioimpact.com/orna-therapeut…
MPM BioImpact tweet media
English
0
0
1
304
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Upon joining our portfolio company @orna_tx as CMO later this month, Frank Neumann, MD, PhD, will join MPM BioImpact as an Entrepreneur Partner, working with our diverse team developing therapies for diseases with high unmet needs. bit.ly/4cM8vIJ
English
0
0
0
325
MPM BioImpact
MPM BioImpact@MPMBioImpact·
MPM BioImpact is pleased to participate in the Series A financing of AstronauTx to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. Read the press release: astronautx.bio/astronautx-clo…
English
1
1
4
927
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Today we’re celebrating our company @ReNAgadeTx, named to Endpoints News list of the 11 most promising biotech companies in 2023. This preclinical-stage genetic medicines company is working to untap the limitless potential of RNA medicine. endpts.com/the-endpoints-…
MPM BioImpact tweet media
English
0
0
0
361
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Our portfolio company @ReCodeTx, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced an extension of its Series B financing. Read the press release here: businesswire.com/news/home/2023…
English
0
0
0
334
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Join MPM BioImpact Partner Brian Goodman at the LSX World Congress in Boston Sept. 13, where he'll share his perspectives on the outlook for venture investors and investing in the science of tomorrow. For more information and to register, visit lsxleaders.com/lsx-usa-congre…
MPM BioImpact tweet media
English
1
0
0
291
MPM BioImpact retweetledi
Boston Cambridge Biotech Networks
Boston Cambridge Biotech Networks@BCBionetwork·
BCBN Feed: RNA startup launches with $300M, Merck partnership: ReNAgade Therapeutics is emerging from stealth with a leadership team hailing from Alnylam Pharmaceuticals and Moderna. The company has about ... #boston #biotech tinyurl.com/2hckmhm4
English
0
1
0
401
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Congratulations to our portfolio co @ReNAgadeTx: $300M+ Series A financing to dramatically transcend boundaries of RNA medicine. Financing led by MPM BioImpact & F2 Ventures. ReNAgade JV with MPM BioImpact-founded @Ornatx provides early validation of its technologies. #biotech
ReNAgade Therapeutics@ReNAgadeTx

We are thrilled to announce the launch of ReNAgade Therapeutics with $300M+ in Series A financing. With our comprehensive deliver, code, edit, insert technologies, we’re unlocking the limitless potential for RNA medicines. renagadetx.com/news

English
0
1
2
781
MPM BioImpact
MPM BioImpact@MPMBioImpact·
Congratulations to our friends and colleagues at MPM portfolio company Entrada Therapeutics on the new partnership with Vertex Pharmaceuticals, bringing $250M of capital to Entrada’s DM1 program and novel EEV approach to intracellular therapeutics.
Entrada Therapeutics@entradatx

We are proud to announce our collaboration with @VertexPharma to discover and develop Endosomal Escape Vehicle (EEVTM)-therapeutics for the potential treatment of myotonic dystrophy type 1, including our late-stage preclinical program ENTR-701. Read more: bit.ly/3uFtQ1n.

English
0
1
3
0
MPM BioImpact
MPM BioImpact@MPMBioImpact·
@orna_tx, a company we and our affiliate @BioImpactCap created, was today named to @endpts list of most promising biotech companies in 2022. Congratulations to our colleague Tom Barnes and the Orna team.
Orna Therapeutics@orna_tx

We are thrilled to share that @endpts has recognized Orna Therapeutics as one of #biotech’s most promising companies in 2022! Click here to read more: endpts.com/the-endpoints-… Congratulations to all other #Endpoints11 awardees!

English
0
1
1
0
MPM BioImpact
MPM BioImpact@MPMBioImpact·
MPM portfolio company @UmojaBiopharma named to @biospace NextGen Bio “Class of 2022” top life sciences startups to watch! Congratulations to our colleague @andyscharenberg and the Umoja team. Read the corresponding BioSpace article below.
Umoja Biopharma@UmojaBiopharma

Our Co-founder & CEO, @andyscharenberg MD, spoke with @Chicat08 in this @biospace article about Umoja’s #unified approach to overcoming limitations of current #CellTherapies. Read the article here: bit.ly/3ectYkh Read more about our science here: bit.ly/3AZbmNz

English
0
1
5
0
MPM BioImpact
MPM BioImpact@MPMBioImpact·
MPM and @BioImpactCap, an MPM affiliate, created #AktisOncology in 2020 to develop a best-in-class, targeted alpha particle radiotherapy platform for treating solid tumors. We are excited for this important next step!
BioSpace@biospace

Aktis Oncology announced Thursday the completion of an $84 million Series A extension financing round to bring its class of targeted radiopharmaceuticals to a large patient pool with a broad range of solid tumors. #AktisOncology #Biotech #BioSpace hubs.li/Q01kWzcd0

English
0
0
3
0

Keşfet

@orna_tx @CullinanTx @ReNAgadeTx @ReCodeTx @devinquinlan @dylanvneel @endpts @UmojaBiopharma